Free Trial

Elanco Animal Health Incorporated (NYSE:ELAN) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Elanco Animal Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate Elanco a “Moderate Buy”: Of 13 analysts covering the stock, nine recommend buying and one strongly recommends buying; the average 12-month price target is $29.75.
  • Latest quarterly results beat expectations: Elanco reported EPS of $0.27 versus the $0.20 consensus and revenue of $1.26 billion versus $1.21 billion, with revenue up 11.3% year over year.
  • The company’s 2026 guidance is EPS of $0.16–$0.19 for Q4 and $1.17–$1.20 for the full year; analysts expect full-year EPS of $1.18.
  • Five stocks we like better than Elanco Animal Health.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $29.75.

A number of equities research analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They set a "buy" rating and a $32.00 target price on the stock. UBS Group raised their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. KeyCorp reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Monday, November 9th. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating for the company in a report on Thursday, October 29th. Finally, Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th.

Check Out Our Latest Stock Analysis on ELAN

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $26.80 on Monday. Elanco Animal Health has a fifty-two week low of $19.40 and a fifty-two week high of $27.98. The company has a market capitalization of $13.40 billion, a P/E ratio of -89.33, a PEG ratio of 2.26 and a beta of 1.73. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.07 and a current ratio of 2.09. The stock has a 50 day moving average price of $23.38 and a two-hundred day moving average price of $23.88.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.07. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. Elanco Animal Health's revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Analysts expect that Elanco Animal Health will post 1.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Timothy J. Bettington sold 4,350 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.00, for a total value of $100,050.00. Following the transaction, the insider directly owned 138,911 shares of the company's stock, valued at approximately $3,194,953. This represents a 3.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shiv O'Neill acquired 3,998 shares of Elanco Animal Health stock in a transaction dated Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider owned 87,832 shares of the company's stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Anchor Investment Management LLC purchased a new position in shares of Elanco Animal Health during the 2nd quarter valued at about $29,000. Covestor Ltd boosted its stake in shares of Elanco Animal Health by 48.2% in the third quarter. Covestor Ltd now owns 1,383 shares of the company's stock worth $31,000 after buying an additional 450 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Elanco Animal Health in the second quarter worth about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Elanco Animal Health in the second quarter worth about $38,000. Finally, Resona Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health during the third quarter worth about $35,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

(Get Free Report)

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

See Also

Analyst Recommendations for Elanco Animal Health (NYSE:ELAN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elanco Animal Health Right Now?

Before you consider Elanco Animal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.

While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines